Amgen Stock News

The Goldman Sachs Group started coverage on shares of Amgen (NASDAQ:AMGN) in a research note released on Monday morning, Price Targets.com reports. The firm issued a buy rating and a $258.00 target price on the medical research companys stock. A number of other equities analysts also recently issued reports on AMGN. SVB Leerink dropped their []

BLINCYTO® (blinatumomab) Data Demonstrate Superior Overall Survival in Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia in Longer Follow-up of Phase 3 Trial First Presentation of Efficacy and Safety Data With Subcutaneous BLINCYTO Administration in Patients With Relapsed or Refractory

DUBLIN--(BUSINESS WIRE)--The "TNF Alpha Inhibitors Global Market Report 2021: COVID-19 Growth and Change to 2030" report has been added to ResearchAndMarkets.com''s offering. The global TNF alpha inhibitors market is expected to grow from $38.85 billion in 2020 to $40.33 billion in 2021 at a compound annual growth rate (CAGR) of 3.8%. The market is expected to reach $45.74 billion in 2025 at a CAGR of 3%. Major players in the TNF alpha inhibitors market are AbbVie Inc., Amgen Inc., Johnson &

Covenant Multifamily Offices LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN) by 14.0% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 5,663 shares of the medical research company’s stock after acquiring an additional 695 shares during the quarter. Covenant Multifamily Offices LLC’s holdings […]

This article was originally published on TipRanks.com Amgen (AMGN) has raised its quarterly cash dividend by 10% to $1. The post Amgen Bumps up Quarterly Dividend by 10% appeared first on Smarter Analyst .

The global Merkel Cell Carcinoma Treatment market size is projected a CAGR of 7.8% during 2021-2027. The rise in the number of cases of merkel cell carcinoma around the world has influenced the demand for novel medications for merkel cell

These three pharmaceutical stocks could buffer your portfolio against further market turbulence.

Amgen carries a number of strong drug franchises and has a burgeoning biosimilar practice. It has a strong track record of capital returns and its dividend yield currently sits well above its historic

A look at two names providing over 10% dividend raises Related Stocks: AMGN , NKE ,

Patriot Investment Management Inc. grew its holdings in Amgen Inc. (NASDAQ:AMGN) by 5.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 9,732 shares of the medical research companys stock after purchasing an additional 520 shares during the period. Patriot Investment Management []

Oak Asset Management LLC lifted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 5.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 64,608 shares of the medical research companys stock after purchasing an additional 3,320 shares during the quarter. Amgen []